应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ELTX Elicio Therapeutics
休市中 08-16 16:00:00 EDT
4.40
+0.09
+2.09%
盘后
4.39
-0.01
-0.23%
16:00 EDT
最高
4.40
最低
4.26
成交量
5,152
今开
4.27
昨收
4.31
日振幅
3.25%
总市值
4,733万
流通市值
2,605万
总股本
1,076万
成交额
2.24万
换手率
0.09%
流通股本
592.13万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Elicio Therapeutics Inc 预计每股亏损 96 美分 - 财报前瞻
Reuters · 08-07
Elicio Therapeutics Inc 预计每股亏损 96 美分 - 财报前瞻
Elicio Therapeutics宣布定价1150万美元的担保公开发行。
智通财经 · 06-28
Elicio Therapeutics宣布定价1150万美元的担保公开发行。
Elicio Therapeutics Inc-用于开发管线的款项
智通财经 · 06-28
Elicio Therapeutics Inc-用于开发管线的款项
Elicio Therapeutics宣布拟提出公开发行。
智通财经 · 06-28
Elicio Therapeutics宣布拟提出公开发行。
Elicio Therapeutics宣布Eli-002 7P开展Amplify-7P 1a期研究的初步无病生存分析
智通财经 · 06-28
Elicio Therapeutics宣布Eli-002 7P开展Amplify-7P 1a期研究的初步无病生存分析
HC Wainwright & Co.:重申Elicio Therapeutics(ELTX.US)评级,由买入调整至买入评级, 目标价由10.
智通财经 · 06-06
HC Wainwright & Co.:重申Elicio Therapeutics(ELTX.US)评级,由买入调整至买入评级, 目标价由10.
Elicio Therapeutics股份有限公司 - 销售协议募集最多4000万美元普通股的说明书可能随时发行和出售。
智通财经 · 06-04
Elicio Therapeutics股份有限公司 - 销售协议募集最多4000万美元普通股的说明书可能随时发行和出售。
Elicio Therapeutics Inc提交文件申请发行总额高达2亿美元的混合股票。-SEC文件
智通财经 · 06-04
Elicio Therapeutics Inc提交文件申请发行总额高达2亿美元的混合股票。-SEC文件
Elicio Therapeutics Inc:作为单一疗法使用的 Eli-002 7P 耐受性良好
智通财经 · 05-24
Elicio Therapeutics Inc:作为单一疗法使用的 Eli-002 7P 耐受性良好
Elicio Therapeutics在2024年Asco年会上公布了正在进行的针对Mkras驱动实体瘤患者Eli-002 7P的1a期研究的初步数据
智通财经 · 05-24
Elicio Therapeutics在2024年Asco年会上公布了正在进行的针对Mkras驱动实体瘤患者Eli-002 7P的1a期研究的初步数据
HC Wainwright & Co.:重申Elicio Therapeutics(ELTX.US)评级,由买入调整至买入评级, 目标价10.
智通财经 · 05-22
HC Wainwright & Co.:重申Elicio Therapeutics(ELTX.US)评级,由买入调整至买入评级, 目标价10.
HC Wainwright & Co.:维持Elicio Therapeutics(ELTX.US)评级,由买入调整至买入评级, 目标价由11.
智通财经 · 05-01
HC Wainwright & Co.:维持Elicio Therapeutics(ELTX.US)评级,由买入调整至买入评级, 目标价由11.
Biophytis盘中异动 早盘股价大跌12.42%
自选股智能写手 · 03-18
Biophytis盘中异动 早盘股价大跌12.42%
Elicio Therapeutics Inc 预计每股亏损 78 美分 - 财报前瞻
Reuters · 03-14
Elicio Therapeutics Inc 预计每股亏损 78 美分 - 财报前瞻
暂无数据
公司概况
公司名称:
Elicio Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Elicio Therapeutics Inc于1998年4月6日在特拉华州成立。该公司是一家临床阶段的生物技术公司,正在开发一系列新型免疫疗法,用于治疗癌症和其他疾病。通过结合免疫学和免疫疗法方面的专业知识,Elicio正在设计研究性两亲(AMP)免疫疗法,旨在精确地靶向和完全接合淋巴结。Elicio是工程淋巴结靶向为一系列侵袭性癌症和传染病生产AMPlifiers,免疫调节剂,佐剂,和疫苗。
发行价格:
--
{"stockData":{"symbol":"ELTX","market":"US","secType":"STK","nameCN":"Elicio Therapeutics","latestPrice":4.4,"timestamp":1723838400000,"preClose":4.31,"halted":0,"volume":5152,"hourTrading":{"tag":"盘后","latestPrice":4.39,"preClose":4.4,"latestTime":"16:00 EDT","volume":39,"amount":171.20999999999998,"timestamp":1723838401536},"delay":0,"floatShares":5921281,"shares":10755830,"eps":-5.168962,"marketStatus":"休市中","marketStatusCode":7,"change":0.09,"latestTime":"08-16 16:00:00 EDT","open":4.27,"high":4.4,"low":4.2601,"amount":22384.208672,"amplitude":0.032459,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.168962,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724054400000},"adr":0,"listingDate":1612501200000,"adjPreClose":4.31,"postHourTrading":{"tag":"盘后","latestPrice":4.39,"preClose":4.4,"latestTime":"16:00 EDT","volume":39,"amount":171.20999999999998,"timestamp":1723838401536},"volumeRatio":1.0041319425240567},"requestUrl":"/m/hq/s/ELTX/tweets","defaultTab":"tweets","newsList":[{"id":"2457682811","title":"Elicio Therapeutics Inc 预计每股亏损 96 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457682811","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457682811?lang=zh_cn&edition=full","pubTime":"2024-08-07 23:02","pubTimestamp":1723042928,"startTime":"0","endTime":"0","summary":" * Elicio Therapeutics Inc 预计在8月9日公布截至2024年6月30日的财报时,季度营收将不会有任何变化(预计) * * LSEG 的分析师平均预计 Elicio Therapeutics Inc 每股亏损 96 美分。* 华尔街对 Elicio Therapeutics Inc 的 12 个月目标价中位数为 10.00 美元,高于其上次收盘价 4.40 美元。8月7日 - 本摘要于北京时间 8 月 7 日 15:02 机器生成。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","LENZ"],"gpt_icon":0},{"id":"2446078365","title":"Elicio Therapeutics宣布定价1150万美元的担保公开发行。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446078365","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446078365?lang=zh_cn&edition=full","pubTime":"2024-06-28 21:00","pubTimestamp":1719579600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","ELTX","BK4139","LENZ"],"gpt_icon":0},{"id":"2446567047","title":"Elicio Therapeutics Inc-用于开发管线的款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2446567047","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446567047?lang=zh_cn&edition=full","pubTime":"2024-06-28 04:05","pubTimestamp":1719518755,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ELTX","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2446567706","title":"Elicio Therapeutics宣布拟提出公开发行。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446567706","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446567706?lang=zh_cn&edition=full","pubTime":"2024-06-28 04:05","pubTimestamp":1719518700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ELTX","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2446674205","title":"Elicio Therapeutics宣布Eli-002 7P开展Amplify-7P 1a期研究的初步无病生存分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2446674205","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446674205?lang=zh_cn&edition=full","pubTime":"2024-06-28 04:01","pubTimestamp":1719518465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2441497792","title":"HC Wainwright & Co.:重申Elicio Therapeutics(ELTX.US)评级,由买入调整至买入评级, 目标价由10.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441497792","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441497792?lang=zh_cn&edition=full","pubTime":"2024-06-06 18:48","pubTimestamp":1717670937,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","LENZ","ELTX","BK4139"],"gpt_icon":0},{"id":"2440443814","title":"Elicio Therapeutics股份有限公司 - 销售协议募集最多4000万美元普通股的说明书可能随时发行和出售。","url":"https://stock-news.laohu8.com/highlight/detail?id=2440443814","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440443814?lang=zh_cn&edition=full","pubTime":"2024-06-04 05:26","pubTimestamp":1717449982,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2440812443","title":"Elicio Therapeutics Inc提交文件申请发行总额高达2亿美元的混合股票。-SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=2440812443","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440812443?lang=zh_cn&edition=full","pubTime":"2024-06-04 05:25","pubTimestamp":1717449932,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","ELTX","LENZ","BK4007"],"gpt_icon":0},{"id":"2437714322","title":"Elicio Therapeutics Inc:作为单一疗法使用的 Eli-002 7P 耐受性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2437714322","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437714322?lang=zh_cn&edition=full","pubTime":"2024-05-24 05:31","pubTimestamp":1716499870,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4139","LENZ","ELTX"],"gpt_icon":0},{"id":"2437143277","title":"Elicio Therapeutics在2024年Asco年会上公布了正在进行的针对Mkras驱动实体瘤患者Eli-002 7P的1a期研究的初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2437143277","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437143277?lang=zh_cn&edition=full","pubTime":"2024-05-24 05:30","pubTimestamp":1716499800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","ELTX","BK4139","LENZ"],"gpt_icon":0},{"id":"2437226819","title":"HC Wainwright & Co.:重申Elicio Therapeutics(ELTX.US)评级,由买入调整至买入评级, 目标价10.","url":"https://stock-news.laohu8.com/highlight/detail?id=2437226819","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437226819?lang=zh_cn&edition=full","pubTime":"2024-05-22 18:37","pubTimestamp":1716374222,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ELTX","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2432525552","title":"HC Wainwright & Co.:维持Elicio Therapeutics(ELTX.US)评级,由买入调整至买入评级, 目标价由11.","url":"https://stock-news.laohu8.com/highlight/detail?id=2432525552","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2432525552?lang=zh_cn&edition=full","pubTime":"2024-05-01 18:17","pubTimestamp":1714558634,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2420474193","title":"Biophytis盘中异动 早盘股价大跌12.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420474193","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2420474193?lang=zh_cn&edition=full","pubTime":"2024-03-18 21:31","pubTimestamp":1710768692,"startTime":"0","endTime":"0","summary":"北京时间2024年03月18日21时31分,Biophytis股票出现波动,股价快速下挫12.42%。截至发稿,该股报0.419美元/股,成交量4.7805万股,换手率0.49%,振幅0.00%。Biophytis股票所在的生物技术行业中,整体涨幅为0.10%。Biophytis公司简介:Biophytis SA 是一家总部位于法国的生物技术公司,专注于开发减缓与衰老相关的退化过程并改善患有与年龄相关疾病的患者的功能结果的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403182131338b434ce3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403182131338b434ce3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BPTS","ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2419848657","title":"Elicio Therapeutics Inc 预计每股亏损 78 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2419848657","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2419848657?lang=zh_cn&edition=full","pubTime":"2024-03-14 04:06","pubTimestamp":1710360369,"startTime":"0","endTime":"0","summary":" * Elicio Therapeutics Inc 预计在3月15日公布截至2023年12月31日的业绩时,季度营收将没有变化(预计) * * LSEG 的分析师平均预计 Elicio Therapeutics Inc 每股亏损 78 美分。* 华尔街对 Elicio Therapeutics Inc 的 12 个月目标价中位数为 11.00 美元,高于其上次收盘价 5.48 美元。3月13日 - 本摘要于北京时间 3 月 13 日 20:06 机器生成。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://elicio.com","stockEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0814},{"period":"3month","weight":-0.5622},{"period":"6month","weight":0.0577},{"period":"1year","weight":-0.5596},{"period":"ytd","weight":-0.4724}],"compareEarnings":[{"period":"1week","weight":0.04},{"period":"1month","weight":-0.0047},{"period":"3month","weight":0.047},{"period":"6month","weight":0.1097},{"period":"1year","weight":0.2705},{"period":"ytd","weight":0.1662}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Elicio Therapeutics Inc于1998年4月6日在特拉华州成立。该公司是一家临床阶段的生物技术公司,正在开发一系列新型免疫疗法,用于治疗癌症和其他疾病。通过结合免疫学和免疫疗法方面的专业知识,Elicio正在设计研究性两亲(AMP)免疫疗法,旨在精确地靶向和完全接合淋巴结。Elicio是工程淋巴结靶向为一系列侵袭性癌症和传染病生产AMPlifiers,免疫调节剂,佐剂,和疫苗。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.218043},{"month":2,"riseRate":0,"avgChangeRate":-0.16654},{"month":3,"riseRate":0.75,"avgChangeRate":0.240014},{"month":4,"riseRate":0.5,"avgChangeRate":-0.026973},{"month":5,"riseRate":0.75,"avgChangeRate":0.162305},{"month":6,"riseRate":0,"avgChangeRate":-0.254842},{"month":7,"riseRate":0.5,"avgChangeRate":0.007352},{"month":8,"riseRate":0.25,"avgChangeRate":-0.076367},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.062554},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.23032},{"month":11,"riseRate":0,"avgChangeRate":-0.124537},{"month":12,"riseRate":0.333333,"avgChangeRate":0.039614}],"exchange":"NASDAQ","name":"Elicio Therapeutics","nameEN":"Elicio Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Elicio Therapeutics(ELTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Elicio Therapeutics(ELTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Elicio Therapeutics,ELTX,Elicio Therapeutics股票,Elicio Therapeutics股票老虎,Elicio Therapeutics股票老虎国际,Elicio Therapeutics行情,Elicio Therapeutics股票行情,Elicio Therapeutics股价,Elicio Therapeutics股市,Elicio Therapeutics股票价格,Elicio Therapeutics股票交易,Elicio Therapeutics股票购买,Elicio Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Elicio Therapeutics(ELTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Elicio Therapeutics(ELTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}